Skip to main content

Translational_Research_and_Interventional_Oncology_Research_Program News

Multi-institutional study of Wilms tumor facilitates enrollment, optimizes treatment

Enrollment and outcomes were similar across racial and ethnic groups for children participating in therapeutic trials for Wilms tumor — the most common pediatric kidney cancer worldwide, according to a recent report in the Journal of the American College of Surgeons.

Tuesday, February 27th, 2024
Molecular Profiles of Tissue Plus Circulating Tumor DNA Can Better Guide Cancer Care

The current standard of care for identifying targetable mutations in cancer treatment is to conduct molecular profiles on tumor tissue samples, but a study published Monday in JAMA Network Open authored by Wade Iams, MD, and colleagues indicates that adding liquid biopsy testing for circulating tumor DNA mutations increases targetable mutation detection rates.

Thursday, February 1st, 2024
3D Ingenuity: Surgeon develops visual aid for real-time pathology consults

Michael Topf, MD, Assistant Professor of Otolaryngology-Head and Neck Cancer Surgery at Vanderbilt wondered why computer-aided design (CAD) technology hadn’t made it into operating rooms as a visual aid for real-time consultations... So he decided to create it.

Thursday, February 1st, 2024
Exceptional Growth for Amyloidosis Care

When the Vanderbilt Amyloid Multidisciplinary Program (VAMP) launched in 2011, it was the first center in Tennessee dedicated to patients with amyloidosis – a rare, systemic disorder that encompasses myriad presentations and organ dysfunctions. Since then, VAMP has paved the way to coordinated care as a major referral center in the southeastern United States, growing to include over a dozen collaborating specialists working to provide structured, multidisciplinary care to adults navigating an amyloidosis diagnosis.

Wednesday, January 31st, 2024
New members of Academy for Excellence in Clinical Medicine selected

Vanderbilt University School of Medicine Academy for Excellence in Clinical Medicine (AECM) has selected 25 new members.

Friday, December 15th, 2023
3D Ingenuity
Three-dimensional scanning and printing systems are now utilized for purposes ranging from same-day dental crowns to prosthetic limbs, so Michael Topf, MD, wondered why computer-aided design (CAD) technology hadn’t made it into operating rooms as a visual aid for real-time consultations.  Surgeons communicate via phone and are dependent upon verbal descriptions from pathologists for guidance […]
Thursday, November 30th, 2023
Innovative Therapy Boosts Survival in Myelodysplastic Syndrome

Researchers find that ASTX727, a new oral combination therapy, can prolong survival in TP53-mutated MDS.

Monday, November 6th, 2023
Being treated for childhood cancer set Jason Schwartz on the path to his life’s work: treating childhood cancer

At the ripe age of 13, Jason Schwartz made a life-changing decision. Amid cancer treatment for Acute Lymphoblastic Leukemia (ALL), Schwartz was handed an incredible gift that would fuel his life’s work.

Wednesday, September 27th, 2023
AI to Address Questions Left by Lung Screenings

Research team refines method for diagnosis of indeterminant lung nodules using artificial intelligence and advanced learning.

Wednesday, August 23rd, 2023
New leaders named to Vanderbilt-Ingram research programs

Seven new leaders have been appointed to guide Vanderbilt-Ingram Cancer Center's research programs.

Thursday, August 10th, 2023
Marshaling First-Line Immunotherapy for CRC
Kristen Ciombor, M.D., reflects on recent wins and opportunities ahead in the precision targeting of colorectal cancer.
Wednesday, July 26th, 2023
Stronger Hearts for Childhood Cancer Survivors

Pediatric oncologists and cardiologists collaborate on reducing cardiotoxic effects of cancer treatment.

Wednesday, June 7th, 2023
Target for Lung-Cancer Subtype Identified

Multifaceted study connects early amplified oncogene MDM2 with outcomes and therapy responses.

Wednesday, June 7th, 2023
Genomic analysis of SCLC tumors reveals subtypes, offers cues toward personalized treatments

The largest genomic analysis ever conducted of small cell lung cancer tumors (SCLC) has identified genetic subtypes and provided insights into the mechanisms of this aggressive and deadly cancer.

Thursday, May 11th, 2023
Trial combines novel therapies for head and neck cancer

Vanderbilt is launching a clinical trial that pairs an experimental vaccine with an established immunotherapy for recurrent, human papilloma virus (HPV)-related oropharyngeal cancer of the head and neck.

Thursday, April 27th, 2023
Vanderbilt-Ingram devises CAR T treatment protocol without hospital stay

Oluwole’s patients often call him “Dr. O,” and he is one of the nation’s top CAR T experts. He is an author of a study published in The New England Journal of Medicine in 2017 that showed CAR T is an effective treatment for refractory large B-cell lymphoma.

Thursday, April 6th, 2023
VUMC researcher selected for Global Scholars Program

Vanderbilt researcher P. Brent Ferrell, MD, is leading one of five projects selected by the 2022 Novartis Institutes for BioMedical Research Global Scholars Program.

Thursday, March 30th, 2023
Researchers discover molecular signature for aggressive thyroid cancer

A Vanderbilt study found that a molecular signature that predicts aggressive thyroid cancer could help guide treatment approaches for patients.

Sunday, February 5th, 2023
VUMC researchers upend dogma about vasopressin production

Vanderbilt investigators have discovered that vasopressin, which has long been thought to be produced only in the brain, is also produced in the kidney.

Thursday, January 5th, 2023
Convalescent plasma improved survival in COVID-19 patients with blood cancers Convalescent plasma improved survival in COVID-19 patients with blood cancers
Treatment with convalescent plasma vastly improved the survival rate of patients hospitalized for COVID-19 who also had hematologic malignances that compromise the immune system, according to new data released by the COVID-19 and Cancer Consortium (CCC19).
Friday, February 5th, 2021
VUMC, Case Western apply artificial intelligence to “customize” oral cancer treatment VUMC, Case Western apply artificial intelligence to “customize” oral cancer treatment
Researchers at Vanderbilt University Medical Center and Case Western Reserve University in Cleveland have been awarded a five-year, $3.3 million grant by the National Cancer Institute to apply artificial intelligence (AI) to help customize treatment for oral cancer patients.
Tuesday, January 5th, 2021
Brian Rini Rini to lead NCI study of COVID-19 in cancer patients
Brian Rini, MD, is leading a study launched by the National Cancer Institute (NCI) that will closely monitor cancer patients who acquire COVID-19 with the goal of providing highly detailed data to guide future care.
Thursday, October 29th, 2020
Lovly to chair foundation’s scientific leadership board Lovly to chair foundation’s scientific leadership board
Christine Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, has been named incoming chair of GO2 Foundation’s Scientific Leadership Board (SLB).
Thursday, October 29th, 2020
Vivian Weiss Grant bolsters Weiss’ pediatric thyroid cancer research
Vivian Weiss, MD, PhD, has been named a 2020 V Scholar and will receive $200,000 from the V Foundation for Cancer Research.
Thursday, November 7th, 2019
3D Illustration of Human Heart Anatomy Study identifies targeted therapy’s cardiac risks
After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.
Thursday, October 3rd, 2019
prostate cancer cells New prostate cancer treatment concept
Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer.
Friday, August 30th, 2019
Michael Savona Grant bolsters research on myelodysplastic syndromes
Michael Savona, MD, professor of Medicine and Cancer Biology, and director of Hematology Research at Vanderbilt-Ingram Cancer Center, has received a competitive grant award from the Edward P. Evans Foundation.
Friday, August 9th, 2019
brain scan Encephalitis identified as rare toxicity of immunotherapy treatment
Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.
Monday, July 22nd, 2019
Mother and teenager Childhood cancer: how it’s different than for adults
The nature of childhood cancer is different than adult cancer, and so is the approach to treatment.
Saturday, June 29th, 2019
Lung cancer Combination therapy improves small-cell lung cancer survival
Patients who received atezolizumab in addition to standard chemotherapy lived two months longer than those treated with chemotherapy alone, according to a recent study published in the New England Journal of Medicine.
Friday, October 26th, 2018
medical samples Liquid biopsies help reveal lung cancer mutations

Cancer investigators led by researchers at Vanderbilt-Ingram Cancer Center have co-developed a liquid biopsy blood-based assay used to identify specific gene mutations associated with the development or relapse of small-cell lung cancer (SCLC)

Thursday, November 2nd, 2017
Horn to lead lung cancer combination therapy trial Horn to lead lung cancer combination therapy trial
Leora Horn, M.D., M.
Sunday, April 2nd, 2017
Study details rare heart risk of certain cancer therapies Study details rare heart risk of certain cancer therapies
Combination therapy using two approved immunotherapy drugs for cancer treatment may cause rare and sometimes fatal cardiac side effects linked to an unexpected immune response. In a study led by Vanderbilt University Medical Center (VUMC) investigators and published in the Nov. 3 issue of the New England Journal of Medicine, researchers describe two cases of […]
Monday, November 7th, 2016
lung cancer VICC trial putting lung cancer therapy to the test
Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis. That head injury may have […]
Thursday, October 20th, 2016
prostate ultrasound New prostate cancer therapy investigated at VUMC
Vanderbilt University Medical Center is the world’s first site to treat a patient in the TULSA-PRO Ablation Clinical Trial (TACT), which employs an emerging therapy that uses MRI guidance and robotically driven therapeutic ultrasound to obtain precise prostate cancer tissue ablation. Investigators, David Penson, M.D.
Thursday, September 22nd, 2016
stem cell transplant VICC treats first patient in Tennessee with novel cellular immunotherapy
For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system. The new CAR-T investigational therapy (known as KTE-C19) is being studied in a clinical trial for patients with aggressive non-Hodgkin Lymphoma (NHL). The trial, called […]
Monday, February 29th, 2016
$51 million NIH grant brings ELVIS to VUMC

Vanderbilt University Medical Center scientists are launching a research platform called ELVIS that is devoted to molecular underpinnings of early-childhood determinants of health.

Tuesday, September 19th, 0023